Pipex Announces European Patent Covering Uses of Oral Trimesta

Pipex Pharmaceuticals has received a European patent that covers the use of estrogens in combination with other FDA-approved multiple sclerosis therapies for the treatment of autoimmune diseases.

The EP1286664 patent covers the use of estrogens and their derivatives at serum concentrations above basal and below pregnancy levels in combination with various immunotherapeutic agents, including Avonex, Betaseron, Copaxone, Rebif and Enbrel for the treatment of Th1-mediated autoimmune diseases, Pipex said. 

The corresponding U.S. and Japanese patents are pending.